Oral drug delivery system
Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
1. A formulation comprising:
a drug selected from buprenorphine, butorphanol, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, and tramadol, or a pharmacologically effective salt thereof;
sucrose acetate isobutyrate (SAIB);
a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and
a solvent in which the CAB is soluble.
2. The formulation of claim 1 , further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.
3. The formulation of claim 1 , further comprising butylhydroxyl toluene.
4. The formulation of claim 1 , wherein the formulation comprises:
from about 20 weight percent to about 90 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 20 weight percent to about 50 weight percent of the solvent.
5. The formulation of claim 1 , wherein the formulation comprises:
from about 30 weight percent to about 70 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.
6. The formulation of claim 5 , wherein the formulation is contained in a capsule comprising gelatin or hydroxyl propylmethyl cellulose.
7. The formulation of claim 6 , wherein the formulation further comprises butylhydroxyl toluene.
8. The formulation of claim 1 , wherein the drug comprises oxycodone or a pharmacologically effective salt thereof.
9. The formulation of claim 1 , wherein the drug comprises a pharmacologically effective salt of oxycodone.
10. A formulation comprising:
an opioid;
sucrose acetate isobutyrate (SAIB);
a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and
a solvent in which the CAB is soluble.
11. The formulation of claim 10 , further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.
12. The formulation of claim 10 , further comprising butylhydroxyl toluene.
13. The formulation of claim 10 , wherein the formulation comprises:
from about 20 weight percent to about 90 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 20 weight percent to about 50 weight percent of the solvent.
14. The formulation of claim 10 , wherein the formulation comprises:
from about 30 weight percent to about 70 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.
15. The formulation of claim 14 , wherein the formulation is contained in a capsule comprising gelatin or hydroxyl propylmethyl cellulose.
16. The formulation of claim 15 , wherein the formulation further comprises butylhydroxyl toluene.
17. A formulation comprising:
oxycodone;
sucrose acetate isobutyrate (SAIB);
a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and
a solvent in which the CAB is soluble.
18. The formulation of claim 17 , further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.
19. The formulation of claim 17 , further comprising butylhydroxyl toluene.
20. The formulation of claim 17 , wherein the formulation comprises:
from about 20 weight percent to about 90 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 20 weight percent to about 50 weight percent of the solvent.
21. The formulation of claim 17 , wherein the formulation comprises:
from about 30 weight percent to about 70 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.
22. The formulation of claim 21 , wherein the formulation is contained in a capsule comprising gelatin or hydroxyl propylmethyl cellulose.
23. The formulation of claim 22 , wherein the formulation further comprises butylhydroxyl toluene.
24. The formulation of claim 17 , wherein the solvent is selected from triacetin and ethyl lactate.
25. A method of preparing a formulation comprising:
an opioid;
sucrose acetate isobutyrate (SAIB);
a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and
a solvent in which the CAB is soluble,
the method comprising:
mixing the SAIB, the CAB, the solvent, and the opioid to form the formulation.
26. The method of claim 25 , wherein the mixing comprises combining the SAIB, the CAB, the solvent, the opioid, and a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.
27. The method of claim 25 , wherein the formulation comprises:
from about 20 weight percent to about 90 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 20 weight percent to about 50 weight percent of the solvent.
28. The method of claim 25 , further comprising encapsulating the formulation in a capsule.
29. The method of claim 28 , wherein the capsule comprises a capsule comprising gelatin or hydroxyl propylmethyl cellulose, wherein the formulation comprises:
from about 30 weight percent to about 70 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB; and
from about 25 weight percent to about 48 weight percent of the solvent, wherein the solvent comprises triacetin or ethyl lactate.
30. The method of claim 29 , wherein the formulation further comprises butylhydroxyl toluene.
31. The method of claim 25 , wherein the opioid comprises oxycodone or a pharmacologically effective salt thereof.